Abivax stock rockets 30% on Eli Lilly takeover speculation

Core Viewpoint - Abivax stock experienced a significant increase of approximately 30% in early trading on the Paris stock exchange following reports that Eli Lilly, a major US pharmaceutical company, is preparing to acquire Abivax for €15 billion (approximately $17.5 billion) [1] Company Summary - Abivax's stock price surged due to acquisition interest from Eli Lilly, indicating strong market confidence in the company's potential value [1] - The reported acquisition amount of €15 billion highlights the strategic importance of Abivax's assets and capabilities in the pharmaceutical sector [1] Industry Summary - The potential acquisition by Eli Lilly reflects ongoing consolidation trends within the pharmaceutical industry, as larger companies seek to enhance their portfolios through strategic acquisitions [1] - The significant valuation of €15 billion for Abivax underscores the competitive landscape and the high stakes involved in biopharmaceutical investments [1]